Page last updated: 2024-08-21

indazoles and Epistaxis

indazoles has been researched along with Epistaxis in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Al-Samkari, H; Gossage, JR; McCrae, KR; Menon, KVN; Parambil, JG; Pederson, DP; Sprecher, DL; Timmerman, KL; Woodard, TD1
Gunderson, CC; Matulonis, U; Moore, KN1
Koc, ON; Parambil, JG; Woodard, TD1

Reviews

1 review(s) available for indazoles and Epistaxis

ArticleYear
Management of the toxicities of common targeted therapeutics for gynecologic cancers.
    Gynecologic oncology, 2018, Volume: 148, Issue:3

    Topics: Anemia; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Autoimmune Diseases; Bevacizumab; Diarrhea; Epistaxis; Fatigue; Female; Genital Neoplasms, Female; Headache; Hemorrhage; Humans; Hypertension; Indazoles; Intestinal Perforation; Molecular Targeted Therapy; Nausea; Neutropenia; Poly(ADP-ribose) Polymerase Inhibitors; Precision Medicine; Proteinuria; Pyrimidines; Risk Assessment; Sulfonamides; Vomiting; Water-Electrolyte Imbalance

2018

Other Studies

2 other study(ies) available for indazoles and Epistaxis

ArticleYear
Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia.
    Angiogenesis, 2022, Volume: 25, Issue:1

    Topics: Anemia; Epistaxis; Humans; Indazoles; Pyrimidines; Retrospective Studies; Sulfonamides; Telangiectasia, Hereditary Hemorrhagic

2022
Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia.
    The Laryngoscope, 2018, Volume: 128, Issue:10

    Topics: Anemia, Iron-Deficiency; Angiogenesis Inhibitors; Bevacizumab; Epistaxis; Erythrocyte Transfusion; Hemoglobins; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Sulfonamides; Telangiectasia, Hereditary Hemorrhagic

2018